Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma

被引:0
作者
Zhu, Hongfei [1 ]
Ye, Bogen [1 ]
Qiao, Zhenguo [2 ]
Zeng, Li [1 ]
Li, Qigen [1 ]
机构
[1] Navy Mil Med Univ, Changhai Hosp, Dept Organ Transplantat, 168 Changhai Rd, Shanghai 200433, Peoples R China
[2] Nantong Univ, Affiliated Wujiang Hosp, Dept Gastroenterol, Suzhou 215200, Jiangsu, Peoples R China
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
advanced hepatocellular carcinoma; hepatectomy; sorafenib; survival; TRANSARTERIAL CHEMOEMBOLIZATION; STAGING SYSTEMS; TUMOR-GROWTH; COMBINATION; MANAGEMENT; RESECTION; APPLICABILITY; RECURRENCE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the efficacy and tolerability of hepatectomy in combination with sorafenib in the treatment of intermediate-advanced hepatocellular carcinoma (HCC). Methods: One hundred and eighty-sixty consecutive patients with intermediate-advanced HCC who were treated with sorafenib were enrolled in this study. They were divided into two groups: sorafenib group (39) and hepatectomy combined with sorafenib group (147). Survival rates of the patients were analyzed by the Kaplan-Meier method. Cox's proportional hazards model was used to analyze variables associated with survival. Adverse events induced by sorafenib were observed and recorded. Results: The median follow-up duration was 13.0 months (range 1-41). There were 77 patients with intermediate HCC (BCLC stage B) (41.4%) and 109 patients with advanced HCC (BCLC stage C) (58.6%). The overall survival was greater in patients with intermediate HCC than in patients with advanced HCC (p=0.011). Surgery before administration of sorafenib did not contribute to overall survival of patients with intermediate HCC (p=0.312). For patients with advanced HCC, the survival of those who underwent surgery before sorafenib was significantly longer than that of patients who received sorafenib alone (15.0 months, 95% CI 12.3-17.7 vs. 8.0 months, 95% CI 5.5-10.5; p=0.024) and surgery before sorafenib was identified as the only predictor of survival for patients with advanced HCC (HR, 0.582; 95% CI, 0.353-0.932; p=0.035). Conclusions: The combination of surgery and sorafenib is safe and significantly prolongs overall survival of patients with advanced HCC.
引用
收藏
页码:1382 / 1389
页数:8
相关论文
共 28 条
  • [1] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [2] Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
    Bruix, J
    Sherman, M
    Llovet, JM
    Beaugrand, M
    Lencioni, R
    Burroughs, AK
    Christensen, E
    Pagliaro, L
    Colombo, M
    Rodés, J
    [J]. JOURNAL OF HEPATOLOGY, 2001, 35 (03) : 421 - 430
  • [3] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [4] The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
    Cabrera, R.
    Pannu, D. S.
    Caridi, J.
    Firpi, R. J.
    Soldevila-Pico, C.
    Morelli, G.
    Clark, V.
    Suman, A.
    George, T. J., Jr.
    Nelson, D. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (02) : 205 - 213
  • [5] Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: Extending the Indication for resection?
    Chang, Wen-Tsan
    Kao, Wei-Yu
    Chau, Gar-Yang
    Su, Chien-Wei
    Lei, Hao-Jan
    Wu, Jaw-Ching
    Hsia, Cheng-Yuan
    Lui, Wing-Yiu
    King, Kuang-Liang
    Lee, Shou-Dong
    [J]. SURGERY, 2012, 152 (05) : 809 - 820
  • [6] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Chang, Yong S.
    Adnane, Jalila
    Trail, Pamela A.
    Levy, Joan
    Henderson, Arris
    Xue, Dahai
    Bortolon, Elizabeth
    Ichetovkin, Marina
    Chen, Charles
    McNabola, Angela
    Wilkie, Dean
    Carter, Christopher A.
    Taylor, Ian C. A.
    Lynch, Mark
    Wilhelm, Scott
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 561 - 574
  • [7] Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method - Analysis of 2010 Taiwanese patients
    Chen, Chien-Hung
    Hu, Fu-Chang
    Huang, Guan-Tarn
    Lee, Po-Huang
    Tsang, Yuk-Ming
    Cheng, Ann-Lii
    Chen, Ding-Shinn
    Wang, Jung-Der
    Sheu, Jin-Chuan
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (09) : 1630 - 1639
  • [8] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [9] Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis
    Duan, Feng
    Wang, Mao Qiang
    Liu, Feng Yong
    Wang, Zhi Jun
    Song, Peng
    Wang, Yan
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (02) : 156 - 163
  • [10] Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
    Dufour, Jean-Francois
    Hoppe, Hanno
    Heim, Markus H.
    Helbling, Beat
    Maurhofer, Olivier
    Szucs-Farkas, Zsolt
    Kickuth, Ralph
    Borner, Markus
    Candinas, Daniel
    Saar, Bettina
    [J]. ONCOLOGIST, 2010, 15 (11) : 1198 - 1204